Results 161 to 170 of about 132,916 (265)

T-lymphocyte Subsets in Cats with Gingivostomatitis

open access: yesJournal of the Japan Veterinary Medical Association, 1999
FUJITA, Keiichi, SAKAI, Takeo
openaire   +2 more sources

Dual Lineages of Langerhans Cells Cooperate to Restore the Immune Barrier after Skin Injury

open access: yesAdvanced Science, EarlyView.
After skin injury, the epidermal immune barrier is rebuilt by two sources of Langerhans cells. Resident Langerhans cells first move into the wound during re‐epithelialization, guided by CXCR2 signaling. Later, recruited monocytes become long‐lived Langerhans cells.
Axel D. Schmitter‐Sánchez   +8 more
wiley   +1 more source

Effects of two immunosuppression regimens on T-lymphocyte subsets in elderly kidney transplant recipients. [PDF]

open access: yesFront Immunol
Freitas GRR   +7 more
europepmc   +1 more source

A Single‐Amino‐Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome‐Targeted Degradation of Membrane Proteins

open access: yesAdvanced Science, EarlyView.
LA‐LYTAC repurposes the cancer‐enriched amino acid transporter LAT1 as a lysosomal trafficking receptor for targeted membrane‐protein degradation. A single phenylalanine‐derived ligand, modularly linked to antibodies or small‐molecule binders, recruits PD‐L1, EGFR, or integrins to LAT1, triggering transporter‐mediated internalization, lysosomal ...
Liquan Zhu   +12 more
wiley   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

open access: yesAdvanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu   +12 more
wiley   +1 more source

Gut microbiota regulation of T lymphocyte subsets during systemic lupus erythematosus. [PDF]

open access: yesBMC Immunol
Lian FP   +8 more
europepmc   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu   +9 more
wiley   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

open access: yesAdvanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy